







Research Article

# Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage

Katrina M. Mirabito Colafella<sup>1,2</sup>,  Daan C.H. van Dorst<sup>2,3</sup>, Rugina I. Neuman<sup>2</sup>, Leni van Doorn<sup>3</sup>,  Karla Bianca Neves<sup>4</sup>,  Augusto C. Montezano<sup>4</sup>, Ingrid M. Garrelts<sup>2</sup>, Richard van Veghel<sup>2</sup>, René de Vries<sup>2</sup>,  Estrellita Uijl<sup>2</sup>, Marian C. Clahsen-van Groningen<sup>5</sup>, Hans J. Baelde<sup>6</sup>, Anton H. van den Meiracker<sup>2</sup>,  Rhian M. Touyz<sup>4</sup>, Willy Visser<sup>2</sup>,  A.H. Jan Danser<sup>2</sup> and Jorie Versmissen<sup>2,7</sup>

<sup>1</sup>Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Australia; <sup>2</sup>Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands; <sup>3</sup>Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; <sup>4</sup>British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom; <sup>5</sup>Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands; <sup>6</sup>Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands; <sup>7</sup>Department of Hospital Pharmacy, Erasmus MC University Medical Centre, Rotterdam, The Netherlands

**Correspondence:** Katrina M. Mirabito Colafella ([katrina.mirabito@monash.edu](mailto:katrina.mirabito@monash.edu))



Vascular endothelial growth factor antagonism with angiogenesis inhibitors in cancer patients induces a ‘preeclampsia-like’ syndrome including hypertension, proteinuria and elevated endothelin (ET)-1. Cyclo-oxygenase (COX) inhibition with aspirin is known to prevent the onset of preeclampsia in high-risk patients. In the present study, we hypothesised that treatment with aspirin would prevent the development of angiogenesis inhibitor-induced hypertension and kidney damage. Our aims were to compare the effects of low-dose (COX-1 inhibition) and high-dose (dual COX-1 and COX-2 inhibition) aspirin on blood pressure, vascular function, oxidative stress, ET-1 and prostanoid levels and kidney damage during angiogenesis-inhibitor therapy in rodents. To this end, Wistar Kyoto rats were treated with vehicle, angiogenesis inhibitor (sunitinib) alone or in combination with low- or high-dose aspirin for 8 days ( $n=5-7$ /group). Our results demonstrated that prostacyclin (PGI<sub>2</sub>) and ET-1 were increased during angiogenesis-inhibitor therapy, while thromboxane (TXA<sub>2</sub>) was unchanged. Both low- and high-dose aspirin blunted angiogenesis inhibitor-induced hypertension and vascular superoxide production to a similar extent, whereas only high-dose aspirin prevented albuminuria. While circulating TXA<sub>2</sub> and prostaglandin F<sub>2α</sub> levels were reduced by both low- and high-dose aspirin, circulating and urinary levels PGI<sub>2</sub> were only reduced by high-dose aspirin. Lastly, treatment with aspirin did not significantly affect ET-1 or vascular function. Collectively our findings suggest that prostanoids contribute to the development of angiogenesis inhibitor-induced hypertension and renal damage and that targeting the prostanoid pathway could be an effective strategy to mitigate the unwanted cardiovascular and renal toxicities associated with angiogenesis inhibitors.

Received: 21 March 2022  
 Revised: 15 April 2022  
 Accepted: 20 April 2022

Accepted Manuscript online:  
 20 April 2022  
 Version of Record published:  
 10 May 2022

## Introduction

Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is essential for tumour growth and metastatic spread. Inhibition of angiogenesis by targeting the vascular endothelial growth factor (VEGF) pathway, either alone or in combination with other therapies such as the latest breakthrough cancer therapy, immune checkpoint inhibitors, is an effective strategy for various types of cancer and leads to prolonged patient survival [1–3]. However, angiogenesis inhibitors can induce severe cardiovascular

and renal toxicities, most frequently hypertension and nephropathy, which may require dose reduction or early termination of therapy. Four types of angiogenesis inhibitors are used clinically: anti-VEGF monoclonal antibodies, VEGF-soluble decoy receptors that capture freely available VEGF, anti-VEGF receptor (VEGFR) monoclonal antibodies and multitargeted tyrosine kinase inhibitors (TKIs) such as sunitinib that have anti-VEGFR activity. Of note, almost all patients experience a rise in blood pressure, with the incidence of hypertension ranging from 4 to 84% depending on the angiogenesis inhibitor used [1], demonstrating that this is a class effect rather than a phenomenon linked to a particular type of angiogenesis inhibitor. Understanding the mechanisms underlying angiogenesis inhibitor-induced hypertension and nephropathy is integral if we are to develop preventative strategies to protect cardiovascular health and allow cancer patients to remain on this lifesaving treatment.

Angiogenesis inhibitor-induced hypertension and kidney damage recapitulate the clinical presentation of preeclampsia, including glomerular endotheliosis, proteinuria and a rise in endothelin (ET)-1 [4]. Since preeclampsia is characterised by high levels of soluble Fms-like tyrosine kinase 1 (sFlt-1), a naturally occurring antagonist of VEGF, it is perhaps not surprising that angiogenesis inhibitors cause a ‘preeclampsia-like’ syndrome and that the underlying mechanisms are thought to be the same [1,5,6]. Here it is of interest to note that cyclo-oxygenase (COX) inhibition with aspirin can prevent the onset of preeclampsia in high-risk patients [6]. Although the initial studies used higher doses of aspirin, resulting in dual COX-1 and COX-2 inhibition [7,8], clinical trials have only investigated the efficacy of low-dose aspirin (i.e., selective COX-1 inhibition) [9,10]. Further, while the protective effect of aspirin is primarily attributed to the restoration of the prostacyclin (PGI<sub>2</sub>)/thromboxane (TXA<sub>2</sub>) ratio [11], other mechanisms such as a reduction in oxidative stress and decreased activation of the ET system are likely to contribute as well [6]. Importantly, these effects may be linked to COX-2 rather than COX-1 dependent prostanoid generation [6].

In the present study, we hypothesised that treatment with aspirin would prevent the development of angiogenesis inhibitor-induced hypertension and kidney damage. To test this hypothesis, we utilised an established model of angiogenesis inhibitor (sunitinib)-induced hypertension and kidney damage [4,12–16]. Our aims were to compare the effects of low-dose (COX-1 inhibition) and high-dose (dual COX-1 and COX-2 inhibition) aspirin on blood pressure, vascular function, oxidative stress, ET-1 and prostanoid levels and kidney damage during angiogenesis-inhibitor therapy in rodents. To this end, male Wistar Kyoto (WKY) rats were treated with vehicle, the angiogenesis inhibitor, sunitinib, alone or in combination with low- or high-dose aspirin for 8 days.

## Materials and methods

### *In vivo* study

Animal experiments were performed at the Erasmus Medical Centre (Rotterdam, The Netherlands). The experiments were approved by the Animal Ethics Committee of the Erasmus University Medical Center Rotterdam (protocol number 118-16-01) and were performed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament and the Netherlands Experiments on Animals Act (Wod, 2014). Male WKY rats were obtained at 10 weeks of age from Charles River, Germany and Janvier Labs, France. Animals were housed in an experimental room with temperature maintained at 21–22°C and a 12-h light–dark cycle. Rats had *ad libitum* access to normal rodent chow and water.

Following a 1-week acclimatisation period, rats were anaesthetised using Forane (isoflurane; inhalation anaesthetic at a dose of 2–3% for induction and then maintained at 2% for the duration of the surgery) for implantation of a radiotelemetry probe (HD-S10, Data Sciences International, MN, U.S.A.) into the abdominal aorta as described previously [15]. Analgesia (temgesic, 0.05 mg/kg s.c.; RB Pharmaceuticals) was administered prior to the surgery and for 2 days afterwards. Following a 10-day recovery period, arterial pressures and heart rate were measured via radiotelemetry as described previously [16]. After establishing baseline values, rats were randomly assigned to one of the four treatment groups: vehicle ( $n=6$ ), the angiogenesis inhibitor sunitinib (14 mg/kg/day; SU;  $n=7$ ) alone or in combination with low-dose aspirin (5 mg/kg/day; SU+low-dose A;  $n=5$ ) or high-dose aspirin (100 mg/kg/day; SU+high-dose A;  $n=5$ ). The low- and high-dose aspirin correspond to human equivalent doses of ~60 and ~1200 mg, respectively. Previous studies have demonstrated that these doses of aspirin result in selective COX-1 inhibition and dual COX-1 and COX-2 inhibition, respectively [17–19]. Some of the data for the vehicle and SU-treated groups and a subset of the data from the SU+high-dose A treated group have been reported recently [16]. Treatments were administered by oral gavage for 8 days. Arterial pressures and heart rate were measured on days 1–6 of treatment. On days 7–8 of treatment, rats were placed into metabolic cages to collect a 24-h urine sample. Thereafter, rats were killed by Forane (isoflurane) anaesthesia overdose and exsanguinated via abdominal vein puncture. Blood was collected into a heparinised tube and then centrifuged at 3000 rpm to obtain plasma. Thereafter, plasma was stored at –80°C for later analysis.

## Ex vivo vascular function

Vascular function was assessed in response to the vasodilator acetylcholine (ACh) or the vasoconstrictor ET-1 in isolated iliac segments as described previously [16]. In additional segments, ACh experiments were performed in the presence (30 min pre-incubation) of NO-synthase inhibition with L- $\omega$ -Nitro-L-arginine methyl ester hydrochloride (L-NAME; 100  $\mu$ mol/l), endothelium-derived hyperpolarising factor inhibition with the intermediate conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel inhibitor TRAM34 (10  $\mu$ mol/l) or the small conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel inhibitor apamin (100  $\mu$ mol/l) or their combination and for ET-1, in the presence of ET<sub>A</sub> receptor (BQ123; 1  $\mu$ mol/l) or ET<sub>B</sub> receptor (BQ788; 1  $\mu$ mol/l) blockade as described previously [16].

## Circulating and urinary measurements

ELISAs were used to determine circulating and urinary ET-1 (ET-1 Quantikine ELISA Kit DET100, R&D systems), PGF<sub>2 $\alpha$</sub>  (circulating PGF<sub>2 $\alpha$</sub>  via 8-isoprostane ELISA Kit No. 516351, Cayman Chemical and urinary PGF<sub>2 $\alpha$</sub>  via Direct 8-iso-PGF<sub>2 $\alpha$</sub>  ELISA Kit ADI-900-091, Enzo Life Sciences), PGI<sub>2</sub> (6-keto-PGF<sub>1 $\alpha$</sub>  ELISA Kit ADI-900-004, Enzo Life Sciences) and TXA<sub>2</sub> (TXB<sub>2</sub> ELISA Kit ADI-900-002, Enzo Life Sciences) levels and the urinary excretion of albumin (Rat ELISA Ab108790, Abcam), neutrophil gelatinase-associated lipocalin (NGAL; Rat lipocalin-2 ELISA Kit Ab207925, Abcam), kidney injury molecule-1 (KIM-1) (Rat TIM-1/KIM-1/HAVCR Quantikine ELISA Kit RKM100, R&D Systems), PGE<sub>2</sub> (Prostaglandin E<sub>2</sub> ELISA Kit No. 514010, Cayman Chemical) and its metabolite, PGE-M (Prostaglandin E Metabolite ELISA Kit No. 514531, Cayman Chemical).

## Markers of oxidative stress

To assess oxidative stress, aortic and renal superoxide anion (O<sub>2</sub><sup>-</sup>) levels were measured by lucigenin chemiluminescence assay as described previously [20]. Aortic, cardiac and renal hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) levels were measured by Amplex Red assay (A22188; Life Technologies, Paisley, U.K.). Aortic mRNA expression of NADPH oxidase (Nox) isoforms 1, 2 and 4 and antioxidant enzymes (SOD1, catalase, GXP1, HO1, Trdx1 and Prdx1) were determined by qPCR using SYBR Green PCR Master Mix (Applied Biosystems, U.K.) and the relative mRNA expression (target gene/18S housekeeping gene) was calculated using the  $\Delta\Delta C_t$  method as described previously [16]. RNA was isolated from the renal cortex using TRIzol (Ambion, Foster City, CA), in accordance with the manufacturer's instructions and reverse transcribed into cDNA using an AMV cDNA synthesis kit (Roche, Indianapolis, IN). Primers used are as described previously [16]. Aortic protein expression of Nox 1, 2 and 4 were determined using Western blotting. Protein (30  $\mu$ g) was separated by electrophoresis on a polyacrylamide gel and transferred to a nitrocellulose membrane. Non-specific-binding sites were blocked with 3% bovine serum albumin in Tris-buffered saline (TBS) solution. Membranes were then incubated with specific antibodies overnight at 4°C. Membranes were washed three times with TBS-Tween20 and incubated with infrared dye-labelled secondary antibodies for 1 h at room temperature. Results were visualised using an Odyssey CLx infrared imaging system (Li-COR Biosciences U.K. Ltd, U.K.) and results were normalised to  $\alpha$ -tubulin protein and are expressed in arbitrary units compared with vehicle group. Antibodies used were as follows: anti- $\alpha$ -tubulin (1:5000; Abcam, U.K.); anti-Nox1 (1:1000; Sigma, U.K.); anti-Nox2 (1:1000; Abcam, U.K.); anti-Nox4 (1:500; Santa Cruz, U.K.).

## Renal mRNA and protein expression

Renal mRNA expression of nephrin, podocin, VEGF, ECE, ET-1, ET<sub>A</sub> receptor, ET<sub>B</sub> receptor, COX-1, COX-2, PGI<sub>2</sub> synthase and TXA<sub>2</sub> synthase were determined via qPCR using iQSYBR Green supermix (Bio-Rad) and the relative mRNA expression (target gene/hypoxanthine phosphoribosyltransferase-1 (*Hprt1*) housekeeping gene) was calculated using the  $\Delta\Delta C_t$  method as described previously [16]. RNA was isolated from the renal cortex using TRIzol (Ambion, Foster City, CA), in accordance with the manufacturer's instructions and reverse transcribed into cDNA using an AMV cDNA synthesis kit (Roche, Indianapolis, IN). Primers used are as described previously [16]. Renal protein abundance of the ET<sub>A</sub> and ET<sub>B</sub> receptors were determined using Western blotting. Protein (40  $\mu$ g) was separated by electrophoresis on a polyacrylamide gel and transferred to a nitrocellulose membrane. Non-specific-binding sites were blocked with 5% bovine serum albumin in TBS solution containing 0.1% Tween-20. Membranes were then incubated with specific antibodies overnight at 4°C. Membranes were washed three times with TBS-Tween20 and incubated with infrared dye-labelled secondary antibodies for 1 h at room temperature. Signals were detected by chemiluminescence (Clarity Western ECL substrate; Bio-Rad) and quantified using Image Studio Lite software. Results were normalised to  $\beta$ -actin protein and are expressed in arbitrary units compared with vehicle group. Antibodies used were as follows: anti-ET<sub>A</sub> (1:1000, Abcam, U.K.), anti-ET<sub>B</sub> (1:1000, Abcam, U.K.),  $\beta$ -actin (1:1000, Cell Signaling 4967).

## Qualitative assessment of kidney morphology

Transverse kidney samples were fixed in 3.5–4% formaldehyde solution for light microscopy evaluation. After fixation, tissues were dehydrated, and paraffin embedded. Deparaffinised 2- $\mu\text{m}$ -thick sections were stained for Periodic Acid–Schiff (PAS) as described previously. In PAS-stained sections, the glomeruli were blindly evaluated by a pathologist (Marian C. Clahsen-van Groningen) for the presence or absence of endothelial cell and epithelial cell swelling and the presence of ischaemia and intraepithelial protein. Kidney biopsies from vehicle and sunitinib-treated animals ( $n=2/\text{group}$ ) were immersed in Karnovsky's fixative containing 2% glutaraldehyde in 0.1 M sodium cacodylate buffer and processed for transmission electron microscopy as described previously [14]. Glomeruli were blindly evaluated by a pathologist (Marian C. Clahsen-van Groningen) for the occurrence of glomerular endotheliosis (endothelial cell swelling, encroachment of the capillary spaces and loss of endothelial fenestrations) and podocyte morphology.

## Statistical analyses

Data are presented as mean  $\pm$  SEM and were analysed using a one-way ANOVA followed by post-hoc  $t$  tests with Holm–Sidak correction to reduce the risk of type-1 error associated with multiple comparisons.  $P \leq 0.05$  was considered to be statistically significant.

## Results


### Low- and high-dose aspirin blunted sunitinib-induced hypertension to a similar extent

Basal systolic and diastolic arterial pressures and heart rate were  $135 \pm 1$  mmHg,  $90 \pm 1$  mmHg and  $333 \pm 5$  bpm, respectively. Sunitinib induced a rapid pressor response, with the increase in systolic and diastolic arterial pressures measuring  $25 \pm 2$  and  $24 \pm 2$  mmHg, respectively, on day 6 of treatment (Figure 1A,B). Low-dose aspirin blunted the systolic pressor response to sunitinib by 31% ( $P < 0.05$  versus sunitinib alone; Figure 1A,D). This effect was slightly greater during co-treatment with high-dose aspirin, such that the rise in systolic arterial pressure in response to sunitinib was attenuated by 49% ( $P < 0.01$  versus sunitinib alone,  $P = 0.16$  versus co-treatment with low-dose aspirin; Figure 1A,D). Similar changes were observed in diastolic arterial pressure during co-treatment with low- and high-dose aspirin (Figure 1B,E). Sunitinib significantly reduced heart rate ( $P < 0.01$  versus vehicle-treated) and this response was unaffected by co-treatment with low- or high-dose aspirin (Figure 1C,F).

To determine whether the effect of aspirin on the pressor response to sunitinib was associated with altered vascular reactivity to ACh and ET-1, concentration–response curves were constructed *ex vivo* in isolated iliac arteries. The vasodilator response to ACh was comparable between the vehicle and sunitinib-treated groups and was unaffected by co-treatment with low- or high-dose aspirin (Figure 2A–D and Table 1). Similarly, in the presence of NOS inhibition (with L-NAME) alone or in combination with endothelium-derived hyperpolarising factor inhibition (with TRAM34 and apamin), the vasodilator response to ACh was reduced by a similar extent between the groups, except for sunitinib group co-treated with high-dose aspirin (Figure 2A–D and Table 1). In the sunitinib only treated group, the vasodilator response to ACh tended to be reduced in the presence of TRAM34 and apamin ( $P = 0.07$  versus control segment; Figure 2B and Table 1). The magnitude of the vasoconstrictor response to ET-1 was similar between the groups and was not significantly altered by ET<sub>A</sub> receptor blockade (with BQ123) or ET<sub>B</sub> receptor blockade (with BQ788) (Figure 2E–H and Table 1). However, in the presence of BQ123 the sensitivity to ET-1 was reduced in all groups such that the curve was shifted rightward (Figure 2E–H and Table 1).


### Effect of low- and high-dose aspirin on circulating ET-1 and prostanoid levels during sunitinib treatment

Circulating ET-1 was higher in the sunitinib-treated groups, however this only reached statistical significance when sunitinib was administered alone ( $P = 0.05$  versus vehicle-treated; Figure 3A). PGI<sub>2</sub>, measured via its stable metabolite 6-keto-PGF<sub>1 $\alpha$</sub> , was increased during treatment with sunitinib alone and this response was unaffected by co-treatment with low-dose aspirin (both  $P < 0.05$  versus vehicle-treated; Figure 3B) and reduced by 30% during co-treatment with high-dose aspirin (Figure 3B). Circulating TXB<sub>2</sub>, the stable metabolite of TXA<sub>2</sub>, was reduced by 67% during treatment with sunitinib and by 93 and 94% during co-treatment with low- and high-dose aspirin respectively (all  $P < 0.05$  versus vehicle-treated; Figure 3C). Consequently, the PGI<sub>2</sub>/TXA<sub>2</sub> ratio was greater during treatment with sunitinib and this reached statistical significance during co-treatment with aspirin (Figure 3D). Circulating PGF<sub>2 $\alpha$</sub> , measured as 8-iso-PGF<sub>2 $\alpha$</sub> , was similar between the vehicle and sunitinib-treated groups and reduced by a similar extent during co-treatment with low- and high-dose aspirin (both  $P < 0.01$  versus vehicle-treated; Figure 3E).



**Figure 1. The effect of treatment on blood pressures and heart rate**

Changes in systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and heart rate (HR) in response to treatment with vehicle, sunitinib (14 mg/kg/day) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A). Time course of changes in (A) SAP, (B) DAP and (C) HR and areas under the curve (AUCs) for the cumulative change in (D) SAP, (E) DAP and (F) HR. Data are presented as mean  $\pm$  SEM ( $n=5-7$ /group). Data were analysed by one-way ANOVA followed by Holm–Sidak’s post-hoc test. \* $P<0.5$ , \*\* $P<0.01$ , \*\*\* $P<0.001$ , \*\*\*\* $P<0.0001$  versus vehicle-treated unless otherwise indicated.




**Figure 2. The effect of treatment on vascular function**

Iliac artery concentration–response curves to (A–D) ACh in the absence or presence of L-NAME (100  $\mu\text{mol/l}$ ), TRAM34 (10  $\mu\text{mol/l}$ ) and apamin (100  $\mu\text{mol/l}$ ) (T+A) or their combination (L-NAME+T+A) and for (E–H) ET-1, in the absence or presence of BQ123 (1  $\mu\text{mol/l}$ ) or BQ788 (1  $\mu\text{mol/l}$ ) following 8 days of treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or in combination with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A) in WKY rats. Data are presented as mean  $\pm$  SEM ( $n=4-7$ /group). Relaxation data are expressed as a percentage of the response to U46619 (0.1–0.3  $\mu\text{mol/l}$ ). See Table 1 for statistical information.

## Both low- and high-dose aspirin prevented sunitinib-induced vascular reactive oxygen species generation

Sunitinib increased aortic  $\text{O}_2^-$  production ( $P=0.01$  versus vehicle-treated; Figure 4A) and this effect was prevented by co-treatment with low- and high-dose aspirin (both  $P<0.05$  versus sunitinib alone; Figure 4A). Conversely, aortic  $\text{H}_2\text{O}_2$  levels were unaffected by treatment (Figure 4B). Aortic mRNA expression of Nox1, which is involved in the production of  $\text{O}_2^-$ , was higher in the sunitinib-treated group ( $P=0.02$  versus vehicle-treated; Figure 4C) and this effect was absent during co-treatment with low- and high-dose aspirin (Figure 4C). There were no significant differences in the aortic mRNA expression of Nox2 and Nox4 (Figure 4D,E). While Nox1 was the most abundant Nox protein expressed, the aortic protein expression of Nox1, Nox2 and Nox 4 was similar between the groups (Figure 4F–K). However, aortic mRNA expression of catalase, which is an  $\text{H}_2\text{O}_2$  scavenger was reduced by sunitinib treatment ( $P=0.002$ ; versus vehicle-treated; Figure 5A) and this effect was prevented by high-dose aspirin ( $P=0.04$  versus sunitinib alone; Figure 5A). Aortic mRNA expression for the antioxidants, SOD1, GPX1, HO1, Prdx or Trdx was similar between the treatment groups (Figure 5B–F). Renal  $\text{O}_2^-$  production and renal and cardiac  $\text{H}_2\text{O}_2$  levels were unaffected by treatment (Figure 6A–C).



**Figure 3. The effect of treatment on circulating endothelin (ET)-1 and prostanoid levels**

Circulating levels of (A) ET-1 and (B) PGI<sub>2</sub>, (C) TXA<sub>2</sub>, (D) the PGI<sub>2</sub>/TXA<sub>2</sub> ratio and (E) PGF<sub>2α</sub> as measured by their metabolites, 6-keto-PGF<sub>1α</sub>, TXB<sub>2</sub>, and 8-iso-PGF<sub>2α</sub> respectively, following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A). Data are presented as mean ± SEM (*n*=5–7/group). Data were analysed using a one-way ANOVA followed by post-hoc *t* tests with Holm–Sidak correction where appropriate. \**P*≤0.05, \*\**P*<0.01 versus vehicle-treated.

**Table 1** pEC<sub>50</sub> and E<sub>max</sub> values for iliac artery concentration–response curves for ACh in the absence or presence of L-NAME (100 μmol/l), TRAM34 (10 μmol/l) and apamin (100 μmol/l) (T+A) or their combination (L-NAME+T+A) and ET-1 in the absence or presence of BQ123 (1 μmol/l) or BQ788 (1 μmol/l) following 8 days of treatment with vehicle, sunitinib (14 mg/kg/day) alone or in combination with low-dose aspirin (5 mg/kg/day; SU+low-dose A) or high-dose aspirin (100 mg/kg/day; SU+high-dose A) in WKY rats

	Vehicle	SU	SU+low-dose A	SU+high-dose A
<b>pEC<sub>50</sub></b>				
ACh	6.7 ± 0.2	6.6 ± 0.1	6.5 ± 0.3	6.3 ± 0.4
ACh+L-NAME	6.9 ± 0.4	7.7 ± 0.6	6.4 ± 0.4	6.6 ± 0.2
ACh+T+A	6.6 ± 0.4	6.7 ± 0.3	6.3 ± 0.4	5.9 ± 0.3
ACh+L-NAME+T+A	7.0 ± 0.5	7.4 ± 0.3	6.4 ± 0.5	6.5 ± 0.4
ET-1	8.5 ± 0.1	8.3 ± 0.2	8.2 ± 0.2	8.0 ± 0.1
ET-1+BQ123	7.5 ± 0.2 <sup>§</sup>	7.5 ± 0.2 <sup>‡</sup>	7.4 ± 0.2 <sup>†</sup>	7.3 ± 0.1 <sup>†</sup>
ET-1+BQ788	8.4 ± 0.1	8.2 ± 0.1	8.2 ± 0.1	7.9 ± 0.1
<b>E<sub>max</sub></b>				
ACh	89 ± 10	77 ± 6	90 ± 4	84 ± 10
ACh+L-NAME	39 ± 13*	36 ± 16*	28 ± 14 <sup>†</sup>	65 ± 6
ACh+T+A	65 ± 18	44 ± 13	80 ± 21	75 ± 12
ACh+L-NAME+T+A	24 ± 4 <sup>†</sup>	37 ± 13*	20 ± 12 <sup>†</sup>	30 ± 17*
ET-1	145 ± 23	132 ± 31	165 ± 14	172 ± 18
ET-1+BQ123	148 ± 37	159 ± 31	202 ± 46	150 ± 37
ET-1+BQ788	149 ± 31	125 ± 35	189 ± 30	200 ± 28

Data are presented as mean ± SEM (n=4–7/group).

\*P<0.5.

<sup>†</sup>P<0.01.

<sup>‡</sup>P<0.001.

<sup>§</sup>P<0.0001, <sup>‡</sup>P<0.001, <sup>†</sup>P<0.01 versus control segment.

## High-dose aspirin, but not low-dose aspirin, prevented the sunitinib-induced increase in albuminuria in association with a reduction in the urinary excretion of 6-keto-PGF<sub>1α</sub>


Sunitinib treatment increased albuminuria and this effect was prevented by co-treatment with high-, but not low-dose aspirin (Figure 7A). Neither the renal mRNA expression of the genes encoding nephrin and podocin, which are essential for the normal functioning of the glomerular filtration barrier, nor the urinary excretion of NGAL and KIM-1, which are markers of tubular damage, were affected by treatment (Figure 7B–E). Qualitative light microscopy evaluation in PAS-stained kidney sections did not suggest any differences in glomerular morphology among the four groups (Supplementary Figure S1A–D). In vehicle and SU-treated rats, qualitative electron microscopy examination revealed mild loss of endothelial fenestrations and endothelial activation in response to SU treatment (Supplementary Figure S2A–D). Glomerular basement membrane thickness remained unaffected by SU treatment compared with vehicle (180 versus 164 nm, respectively).

The urinary excretion of 6-keto-PGF<sub>1α</sub> was 12-fold higher following treatment with sunitinib alone, 15-fold during co-treatment with low-dose aspirin and 7-fold during co-treatment with high-dose aspirin compared with vehicle-treated rats (all P<0.05; Figure 8A). The urinary excretion of TXB<sub>2</sub> was reduced during treatment with sunitinib alone and during co-treatment with aspirin (all P<0.05 versus vehicle-treated; Figure 8B). Conversely, the urinary excretion of 8-iso-PGF<sub>2α</sub>, PGE<sub>2</sub> and PGE-M were unaffected by treatment (Figure 8C–E). Renal mRNA expression of the genes encoding VEGF, COX-1, COX-2, PGI<sub>2</sub> synthase and TXA<sub>2</sub> synthase were unaffected by treatment (Supplementary Figure S3A–E). Similarly, renal activation of the ET system, as assessed by mRNA expression of the genes encoding ECE, ET-1, ET<sub>A</sub> receptor and ET<sub>B</sub> receptor and the protein expression of the ET<sub>A</sub> and ET<sub>B</sub> receptors were unaffected by treatment (Figure 9A–G).

## Discussion

The main findings of the present study were: (i) angiogenesis inhibitor-induced hypertension and renal injury is associated with an up-regulation in circulating and urinary PGI<sub>2</sub> levels while TXA<sub>2</sub>, PGF<sub>2α</sub> and PGE<sub>2</sub> levels remained unchanged or decreased (as reported previously [16]), (ii) both low- and high-dose aspirin blunted angiogenesis






**Figure 4. The effect of treatment on vascular oxidative stress**

Aortic (A) superoxide ( $O_2^-$ ) generation and (B)  $H_2O_2$  production, the mRNA expression of the pro-oxidant Nox isoforms (C) Nox1, (D) Nox2 and (E) Nox4 and Western blot of (F) Nox1, (G) Nox2 and (H) Nox4 and (I–K) their quantification relative to  $\alpha$ -tubulin, respectively, following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A). Aortic mRNA expression is normalised to the internal housekeeping gene 18S and are expressed relative to the vehicle-treated group. Data are presented as mean  $\pm$  SEM ( $n=4-7$ /group). Data were analysed using a one-way ANOVA followed by post-hoc  $t$  tests with Holm–Sidak’s correction where appropriate. \* $P < 0.05$ , \*\* $P < 0.01$  versus vehicle-treated unless otherwise indicated.


inhibitor-induced hypertension and vascular superoxide production to a similar extent, whereas only high-dose aspirin prevented albuminuria, (iii) while circulating  $TXA_2$  and  $PGF_{2\alpha}$  levels were reduced by both low- and high-dose aspirin, circulating and urinary levels of  $PGI_2$  were only reduced by high-dose aspirin and (iv) treatment with aspirin did not significantly affect ET-1 or vascular function. Collectively our findings suggest that prostanoids, and in particular  $PGI_2$ , contribute the development of angiogenesis inhibitor-induced hypertension and renal damage and that targeting the prostanoid pathway could be an effective strategy to mitigate the unwanted cardiovascular and renal toxicities associated with angiogenesis inhibitors (Figure 10).

Since VEGF stimulates the production of  $PGI_2$ , angiogenesis-inhibitor therapy is thought to lead to a reduction in  $PGI_2$ , thereby contributing to the rise in blood pressure and increased thrombotic tendency [21]. However, this is yet to be confirmed in patients. Our data in an established rodent model of angiogenesis inhibitor-induced hypertension and renal injury argues against this concept [16]. The up-regulation in  $PGI_2$  during angiogenesis-inhibitor therapy likely occurs as a protective mechanism. The concentration of  $PGI_2$ , which is dependent on the abundance of COX-1, COX-2 and  $PGI_2$  synthase, is integral in determining its effects on vascular tone and renal function. At physiological concentrations,  $PGI_2$  stimulates its own receptor, the prostacyclin prostanoid (IP) receptor, to elicit vasodilation and reductions in vascular remodelling, inflammation and thrombosis. However, IP receptors are desensitised and internalised after activation [22,23] and at higher concentrations, IP receptors become saturated. In this situation  $PGI_2$  may




**Figure 5. The effect of treatment on the vascular expression of antioxidants**

Aortic mRNA expression of the antioxidant systems (A) catalase (B) SOD1, (C) HO1, (D) GPX1, (E) Trdx1 and (F) Prdx1 following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A). Aortic mRNA expression is normalised to the internal housekeeping gene 18S and are expressed relative to the vehicle-treated group. Data are presented as mean  $\pm$  SEM ( $n=4-7$ /group). Data were analysed using a one-way ANOVA. \* $P<0.05$ , \*\* $P<0.01$  versus vehicle-treated unless otherwise indicated.




**Figure 6. The effect of treatment on renal and cardiac oxidative stress**

Renal (A) superoxide ( $O_2^-$ ) generation and (B) renal and (C) cardiac  $H_2O_2$  production following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A) in WKY rats. Data are presented as mean  $\pm$  SEM ( $n=5-7$ /group). Data were analysed using a one-way ANOVA.




**Figure 7. The effect of treatment on renal injury**

Markers of renal injury following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A) in WKY rats. (A) Albuminuria, the renal mRNA expression of (B) nephritin and (C) podocin and the urinary excretion of (D) NGAL and (E) KIM-1. Renal mRNA expression is normalised to the internal housekeeping gene, *Hprt1*, and is expressed relative to the vehicle-treated group. Data are presented as mean  $\pm$  SEM ( $n=5-7$ /group). Data were analysed using a one-way ANOVA. \* $P<0.05$  versus vehicle-treated.



**Figure 8. The effect of treatment on urinary prostanoid levels**


The urinary excretion of (A) PGI<sub>2</sub>, (B) TXA<sub>2</sub> and (C) PGF<sub>2α</sub> as measured by their metabolites, 6-keto-PGF<sub>1α</sub>, TXB<sub>2</sub>, and 8-iso-PGF<sub>2α</sub>, respectively, and (D) PGE<sub>2</sub> and (E) its metabolite, PGE-M, following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A) in WKY rats. Data are presented as mean ± SEM (*n*=5–7/group). Data were analysed using a one-way ANOVA followed by post-hoc *t* tests with Holm–Sidak’s correction where appropriate. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001 versus vehicle-treated.



**Figure 9. The effect of treatment on renal expression of components of the endothelin (ET) system**

Renal mRNA expression of (A) endothelial-converting enzyme (ECE), (B) ET-1, the ET receptors, (C) ET<sub>A</sub> receptor (ET<sub>A</sub> R) and (D) ET<sub>B</sub> receptor (ET<sub>B</sub> R), and (E) Western blot of ET<sub>A</sub> R and ET<sub>B</sub> R and (F–G) their quantification relative to β-actin, respectively, following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A). Renal mRNA expression is normalised to the internal housekeeping gene, *Hprt1*, and is expressed relative to the vehicle-treated group. Data are presented as mean ± SEM (n=5–7/group). Data were analysed using a one-way ANOVA.

## Anti-VEGF Ab, Anti-VEGFR Ab, VEGF trap, sFlt-1



**Figure 10. Working hypothesis of the role of the prostanoid pathway in angiogenesis inhibitor-induced hypertension and renal injury**

Treatment with angiogenesis inhibitors (VEGF antibodies (Abs), VEGFR Ab, VEGF trap, or TKIs), as well as elevated levels of sFlt-1 (a soluble VEGFR) in preeclampsia all lead to disturbed VEGF signaling, thereby increasing ET-1. This causes hypertension and renal injury via endothelin type A (ET<sub>A</sub>) receptor stimulation. Such stimulation is accompanied by reactive oxygen species (ROS) formation and COX type 1 and type 2 (COX-1/COX-2)-mediated PGI<sub>2</sub> production. Normally, binding of PGI<sub>2</sub> to its prostacyclin (IP) receptor results in beneficial vascular and renal effects, and thus initially this may be protective. Yet, in case of excessive PGI<sub>2</sub> production, PGI<sub>2</sub> can additionally stimulate other prostanoid receptors such as the thromboxane (TP) receptor, the main signaling receptor for TXA<sub>2</sub>, acting as an endothelium-derived contracting factor (EDCF). This could contribute to angiogenesis inhibitor-induced hypertension and nephrotoxicity. The present study has found that low-dose aspirin (resulting in selective COX-1 inhibition and TXA<sub>2</sub> suppression) ameliorates TKI-induced hypertension, while high-dose aspirin (additionally resulting in COX-2 inhibition and PGI<sub>2</sub> suppression) prevents renal injury.

activate other prostanoid receptors to induce IP-like effects via the stimulation of prostaglandin E prostanoid (EP) 2, EP4 and prostaglandin D prostanoid (DP) receptors or to functionally opposing effects via stimulation of thromboxane prostanoid (TP), prostaglandin F prostanoid (FP), EP1 or EP3 receptors. Since the sensitivity of PGI<sub>2</sub> is greater for TP receptors than FP, EP1 and EP3 receptors [24], it is likely that high levels of PGI<sub>2</sub> during angiogenesis-inhibitor therapy primarily lead to the stimulation of TP receptors. In agreement with this hypothesis, it has been demonstrated in mice that sFlt-1-induced hypertension is abolished by high-dose aspirin or picotamide, which is a dual TXA<sub>2</sub> synthase and TP receptor antagonist [25]. This is also consistent with the pathophysiology of preeclampsia, in that the beneficial effect of low-dose aspirin is primarily attributed to a reduction in TXA<sub>2</sub> [6], and hence, reduced TP receptor activation. Further, previous studies have demonstrated during pathological situations such as hypertension, obesity and diabetes, that PGI<sub>2</sub> elicits vasoconstriction via stimulation of TP receptors [24,26–31]. A caveat of this is that this phenomenon is mainly studied in aortic vessels, which may explain why we did not detect any changes in the vasodilator response to ACh in the presence or absence of NO synthase inhibition with L-NAME or calcium channel blockade with apamin and TRAM 34 in our experiments which were conducted in segments of isolated iliac vessels. Here, we must also acknowledge that a limitation of our study is that the vascular function experiments were performed in iliac vessels which are not a resistance vessel. Detailed *in vivo* and *in vitro* studies are required to dissect out the contribution of the various prostanoid receptors to the effects of PGI<sub>2</sub> during angiogenesis-inhibitor therapy.

In the present study, low- and high-dose aspirin blunted the pressor response to sunitinib by a similar extent, suggesting that COX-1-dependent PGI<sub>2</sub> generation contributes to angiogenesis inhibitor-induced hypertension. This is in-line with previous studies in the spontaneously hypertensive rat demonstrating a key role for COX-1-dependent PGI<sub>2</sub> generation in endothelium-dependent contractions, such that PGI<sub>2</sub> acts as an endothelium-derived contracting factor (EDCF). Yet, we did not observe a reduction in PGI<sub>2</sub> in the sunitinib group that was co-treated with low-dose aspirin. This may be explained by the fact that blood samples were collected at the end of day 8 of treatment, i.e., 24 h after the last dose of aspirin was administered. Previous studies have demonstrated that recovery from low-dose aspirin-induced inhibition of endothelial PGI<sub>2</sub> formation is complete 24 h after the last dose, suggesting that COX-1 is rapidly turned over in the endothelium, at least in humans [32]. Similarly, following treatment with aspirin in cultured vascular endothelial cells from humans, rats and bovine, recovery of PGI<sub>2</sub> production took up to 24 h [33]. However, in this study there was no discrimination between COX-1 and COX-2-dependent PGI<sub>2</sub> generation. The 30% reduction in circulating PGI<sub>2</sub> observed in sunitinib group that was co-treated with high-dose aspirin likely reflects a reduction in COX-2 dependent PGI<sub>2</sub> generation. Further, while circulating TXA<sub>2</sub> and PGF<sub>2α</sub> levels were unchanged during treatment with sunitinib alone, co-treatment with low- and high-dose aspirin significantly reduced these prostanoids. Thus, it is likely that reductions in these prostanoids contributed to the attenuated pressor response to sunitinib during co-treatment with low- and high-dose aspirin. As such, we postulate that COX inhibition (such as that achieved with aspirin) will exert greater protective effects during angiogenesis-inhibitor therapy than targeting a specific prostanoid or prostanoid receptor. Further studies are warranted to test this hypothesis.

The up-regulation in vascular O<sub>2</sub><sup>-</sup> during treatment with sunitinib alone most likely contributed to the effects of COX-1-dependent PGI<sub>2</sub> generation on vascular tone. It is known that O<sub>2</sub><sup>-</sup> facilitates EDCF-mediated contractions, either directly by acting as an EDCF or indirectly by reducing the bioavailability of NO and stimulating COX-dependent prostanoid generation. In canine basilar artery, endothelium-dependent contractions are prevented by SOD, which converts O<sub>2</sub><sup>-</sup> into H<sub>2</sub>O<sub>2</sub>, but not by catalysis which scavenges H<sub>2</sub>O<sub>2</sub> [34]. Similarly, in spontaneously hypertensive rats, reactive oxygen species (ROS)-dependent EDCF-mediated contractions were prevented by SOD, indomethacin (a non-specific COX inhibitor). These observations suggest an important role for O<sub>2</sub><sup>-</sup> in EDCF-mediated contractions. However, we previously demonstrated that the SOD mimetic tempol does not alter the pressor response to sunitinib in rats [4]. Thus, the increase in O<sub>2</sub><sup>-</sup> seems to be secondary to the rise in ET-1 and PGI<sub>2</sub> during treatment with sunitinib. Consistent with this hypothesis, it has been shown that ET-1 up-regulates COX-1 and COX-2 via ROS, with increased aortic Nox activity and a reduction in SOD [35]. Further, in the present study, treatment with both high- and low-dose prevented the sunitinib-induced increase in O<sub>2</sub><sup>-</sup>, suggesting that the up-regulation in O<sub>2</sub><sup>-</sup> during angiogenesis-inhibitor therapy is COX-dependent.

Activation of the ET likely plays a key role in the activation of the prostanoid biosynthesis pathway during angiogenesis-inhibitor therapy [16]. In preclinical studies, we, and others, have demonstrated that ET<sub>A/B</sub> or ET<sub>A</sub> receptor blockade blunts angiogenesis inhibitor-induced hypertension and proteinuria [4,16,36,37]. Importantly, we recently demonstrated that ET<sub>A</sub> receptor blockade lowers PGI<sub>2</sub> to a similar extent as dual COX inhibition during sunitinib-induced hypertension [16]. ET-1 leads to an up-regulation of both COX-1 and COX-2, with intrarenal or systemic administration of ET-1 augmenting plasma PGI<sub>2</sub> [31]. In addition to ET-1 [38], other factors such as inflammatory mediators e.g., nuclear factor-κB (NF-κB) [39], hyperosmolality [40] and hypoxia [41] are key drivers for an up-regulation in COX-2. Angiogenesis inhibitors are known to cause hypoxia-induced up-regulation of COX-2, with



concomitant COX-2 inhibition resulting in synergistic effects with angiogenesis-inhibitor therapy as PGE<sub>2</sub> is an angiogenic factor [42]. Thus, COX-2, and hence PGI<sub>2</sub>, may be up-regulated during angiogenesis-inhibitor therapy due to hypoxia (independent of ET-1) and/or the up-regulation in ET-1.

In the present study, albuminuria was increased during sunitinib treatment, yet we did not detect a significant difference in the renal mRNA expression of the podocyte-specific molecules, podocin or nephrin. This is consistent with clinical data which reported that the cumulative dose of bevacizumab is positively correlated with albuminuria rather than the urinary mRNA expression nephrin, podocin and VEGF-A [43]. Also, transmission electron micrographs demonstrated that sunitinib induced a loss of endothelial fenestrations and mild endothelial activation, which can be indicative of glomerular endothelial injury [44]. Importantly, high-dose aspirin, but not low-dose aspirin, completely prevented the development of sunitinib-induced albuminuria and this effect was associated with a reduction in urinary PGI<sub>2</sub> excretion. The latter finding is in contrast with Robinson et al., who did not observe a change in urinary PGI<sub>2</sub> after angiogenesis-inhibitor therapy in patients [45]. Nevertheless, our data suggest that angiogenesis inhibitor-induced renal injury is mediated, at least in part, via COX-2-dependent PGI<sub>2</sub> generation. Consistent with the rise in circulating PGI<sub>2</sub>, we postulate that the massive up-regulation of renal PGI<sub>2</sub> production during angiogenesis-inhibitor therapy most likely occurs as a protective mechanism. PGI<sub>2</sub> plays a critical role in the maintenance of renal blood flow and glomerular filtration rate when actual or effective circulating volume is decreased by blunting vasoconstriction of the pre-glomerular afferent arteriole [46]. Thus, the up-regulation in PGI<sub>2</sub> may occur to offset renal NO deficiency [4,47] and the shift in the pressure–natriuresis curve [13,47] during angiogenesis-inhibitor therapy. Further studies are necessary to delineate the effect of PGI<sub>2</sub> on renal autoregulation and pressure-natriuresis during angiogenesis-inhibitor therapy and whether blocking COX-2 to prevent the kidney injury associated with these drugs will adversely affect renal function.

## Conclusion

The present study provides a rationale for the use of COX inhibitors, particularly COX-2 inhibition, for the prevention of angiogenesis inhibitor-induced hypertension and renal injury. Theoretically, COX inhibition is an attractive option in patients receiving angiogenesis inhibitor therapy as other benefits including a reduction in thrombotic tendency which is COX-1/TP receptor mediated [21,48] and the inhibition of tumour growth and prevention of resistance to angiogenesis-inhibitor therapy, which are both linked to COX-2 [49–53], are likely to be present as well. Further studies are warranted to determine the contribution of the prostanoid pathway to angiogenesis inhibitor-induced hypertension and renal injury and the potential of targeting this pathway as novel strategy to prevent these unwanted effects.

## Clinical perspectives

- **Background as to why the study was undertaken:** Understanding the mechanisms underlying angiogenesis inhibitor-induced hypertension and nephropathy is integral if we are to develop preventative strategies to protect cardiovascular health and allow cancer patients to remain on this life-saving treatment.
- **A brief summary of the results:** Our data demonstrate that PGI<sub>2</sub> is paradoxically up-regulated during angiogenesis-inhibitor therapy. Low-dose aspirin (COX-1 inhibition) and high-dose aspirin (dual COX inhibition) blunted angiogenesis inhibitor-induced hypertension to a similar extent, whereas only high-dose aspirin prevented albuminuria.
- **The potential significance to human health and disease:** Our results uncover a novel role for PGI<sub>2</sub> during angiogenesis-inhibitor therapy and suggest that targeting the prostanoid pathway may be a novel strategy to prevent angiogenesis inhibitor-induced hypertension and kidney damage.

## Data Availability

All supporting data are included within the article.

## Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

## Funding

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia CJ Martin Fellowship [grant number GNT1112125 (to Katrina M. Mirabito Colafella)]; the Foundation Lijf en Leven (to A. H. Jan Danser and Anton H. van den Meiracker); the British Heart Foundation [grant numbers RE/18/6/34217, CH/12/4/29762 (to Rhian M. Touyz)]; and the Walton Fellowship from the University of Glasgow (to Augusto C. Montezano).

## Open Access

Open access for this article was enabled by the participation of Monash University in an all-inclusive *Read & Publish* agreement with Portland Press and the Biochemical Society under a transformative agreement with CAUL.

## CRedit Author Contribution

**Katrina M. Mirabito Colafella:** Conceptualisation, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing—original draft, Project administration, Writing—review & editing. **Daan C.H. van Dorst:** Data curation, Formal analysis, Methodology, Writing—review & editing. **Rugina I. Neuman:** Data curation, Formal analysis, Writing—review & editing. **Leni van Doorn:** Data curation, Formal analysis, Writing—review & editing. **Karla Bianca Neves:** Conceptualisation, Data curation, Formal analysis, Methodology, Writing—review & editing. **Augusto C. Montezano:** Conceptualisation, Data curation, Formal analysis, Methodology, Writing—review & editing. **Ingrid M. Garrelds:** Data curation, Methodology, Writing—review & editing. **Richard van Veghel:** Data curation, Formal analysis, Methodology, Writing—review & editing. **René de Vries:** Conceptualisation, Data curation, Formal analysis, Methodology, Writing—review & editing. **Estrellita Uijl:** Data curation, Formal analysis, Methodology, Writing—review & editing. **Marian C. Clahsen-van Groningen:** Data curation, Investigation, Visualisation, Methodology, Writing—review & editing. **Hans J. Baelde:** Conceptualisation, Data curation, Formal analysis, Methodology, Writing—review & editing. **Anton H. van den Meiracker:** Conceptualisation, Supervision, Funding acquisition, Project administration, Writing—review & editing. **Rhian M. Touyz:** Conceptualisation, Resources, Supervision, Funding acquisition, Methodology, Writing—review & editing. **Willy Visser:** Conceptualisation, Resources, Supervision, Methodology, Writing—review & editing. **A.H. Jan Danser:** Conceptualisation, Supervision, Funding acquisition, Methodology, Project administration, Writing—review & editing. **Jorie Versmissen:** Conceptualisation, Supervision, Funding acquisition, Project administration, Writing—review & editing.

## Abbreviations

ACh, acetylcholine; COX, cyclo-oxygenase; EDCF, endothelium-derived contracting factor; ET, endothelin; *Hprt1*, hypoxanthine phosphoribosyltransferase-1; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; KIM-1, kidney injury molecule-1; L-NAME, L-ω-Nitro-L-arginine methyl ester hydrochloride; NGAL, neutrophil gelatinase-associated lipocalin; Nox, NADPH oxidase; PAS, Periodic Acid–Schiff; PGE, prostaglandin E; PGE-M, prostaglandin E metabolite; PGI<sub>2</sub>, prostacyclin; ROS, reactive oxygen species; sFlt-1, soluble Fms-like tyrosine kinase 1; SU, sunitinib; TBS, Tris-buffered saline; TKI, tyrosine kinase inhibitor; TXA<sub>2</sub>, thromboxane; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; WKY, Wistar Kyoto.

## References

- Versmissen, J., Mirabito Colafella, K.M., Koolen, S.L.W. and Danser, A.H.J. (2019) Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. *Cardiovasc. Res.* **115**, 904–914, <https://doi.org/10.1093/cvr/cvz022>
- Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D. et al. (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N. Engl. J. Med.* **380**, 1116–1127, <https://doi.org/10.1056/NEJMoa1816714>
- Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T. et al. (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N. Engl. J. Med.* **380**, 1103–1115, <https://doi.org/10.1056/NEJMoa1816047>
- Kappers, M.H., Smedts, F.M., Horn, T., van Esch, J.H., Sleijfer, S., Leijten, F. et al. (2011) The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. *Hypertension* **58**, 295–302, <https://doi.org/10.1161/HYPERTENSIONAHA.111.173559>
- Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L. et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N. Engl. J. Med.* **349**, 427–434, <https://doi.org/10.1056/NEJMoa021491>
- Mirabito Colafella, K.M., Neuman, R.I., Visser, W., Danser, A.H.J. and Versmissen, J. (2020) Aspirin for the prevention and treatment of pre-eclampsia: a matter of COX-1 and/or COX-2 inhibition? *Basic Clin. Pharmacol. Toxicol.* **127**, 132–141, <https://doi.org/10.1111/bcpt.13308>
- Goodlin, R.C., Haesslein, H.O. and Fleming, J. (1978) Aspirin for the treatment of recurrent toxemia. *Lancet* **2**, 51, [https://doi.org/10.1016/S0140-6736\(78\)91367-3](https://doi.org/10.1016/S0140-6736(78)91367-3)
- Crandon, A.J. and Isherwood, D.M. (1979) Effect of aspirin on incidence of pre-eclampsia. *Lancet* **1**, 1356, [https://doi.org/10.1016/S0140-6736\(79\)91996-2](https://doi.org/10.1016/S0140-6736(79)91996-2)

- 9 Roberge, S., Nicolaidis, K., Demers, S., Hyett, J., Chaillet, N. and Bujold, E. (2017) The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am. J. Obstet. Gynecol.* **216**, 110–120, e6., <https://doi.org/10.1016/j.ajog.2016.09.076>
- 10 Rolnik, D.L., Wright, D., Poon, L.C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C. et al. (2017) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. *N. Engl. J. Med.* **377**, 613–622, <https://doi.org/10.1056/NEJMoa1704559>
- 11 Majed, B.H. and Khalil, R.A. (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. *Pharmacol. Rev.* **64**, 540–582, <https://doi.org/10.1124/pr.111.004770>
- 12 Kappers, M.H., van Esch, J.H., Sluiter, W., Sleijfer, S., Danser, A.H. and van den Meiracker, A.H. (2010) Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. *Hypertension* **56**, 675–681, <https://doi.org/10.1161/HYPERTENSIONAHA.109.149690>
- 13 Lankhorst, S., Baelde, H.J., Claassen-van Groningen, M.C., Smedts, F.M., Danser, A.H. and van den Meiracker, A.H. (2016) Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. *Nephrol. Dial. Transplant.* **31**, 914–921, <https://doi.org/10.1093/ndt/gfv410>
- 14 Lankhorst, S., Baelde, H.J., Kappers, M.H., Smedts, F.M., Hansen, A., Claassen-van Groningen, M.C. et al. (2015) Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib. *Hypertension* **66**, 543–549, <https://doi.org/10.1161/HYPERTENSIONAHA.115.05435>
- 15 Lankhorst, S., Kappers, M.H., van Esch, J.H., Smedts, F.M., Sleijfer, S., Mathijssen, R.H. et al. (2014) Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. *Hypertension* **64**, 1282–1289, <https://doi.org/10.1161/HYPERTENSIONAHA.114.04187>
- 16 Mirabito Colafella, K.M., Neves, K.B., Montezano, A.C., Garredts, I.M., van Veghel, R., de Vries, R. et al. (2020) Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. *Cardiovasc. Res.* **116**, 1779–1790, <https://doi.org/10.1093/cvr/cvz260>
- 17 Ornelas, A., Zacharias-Millward, N., Menter, D.G., Davis, J.S., Lichtenberger, L., Hawke, D. et al. (2017) Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. *Cancer Metastasis Rev.* **36**, 289–303, <https://doi.org/10.1007/s10555-017-9675-z>
- 18 Dovizio, M., Bruno, A., Tacconelli, S. and Patrignani, P. (2013) Mode of action of aspirin as a chemopreventive agent. *Recent Results Cancer Res.* **191**, 39–65, [https://doi.org/10.1007/978-3-642-30331-9\\_3](https://doi.org/10.1007/978-3-642-30331-9_3)
- 19 Blanco, F.J., Guitián, R., Moreno, J., de Toro, F.J. and Galdo, F. (1999) Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. *J. Rheumatol.* **26**, 1366–1373
- 20 Neves, K.B., Rios, F.J., van der Mey, L., Alves-Lopes, R., Cameron, A.C., Volpe, M. et al. (2018) VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. *Hypertension* **71**, 638–647, <https://doi.org/10.1161/HYPERTENSIONAHA.117.10490>
- 21 Touyz, R.M., Herrmann, S.M.S. and Herrmann, J. (2018) Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. *J. Am. Soc. Hypertens.* **12**, 409–425, <https://doi.org/10.1016/j.jash.2018.03.008>
- 22 Smyth, E.M., Li, W.H. and FitzGerald, G.A. (1998) Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. *J. Biol. Chem.* **273**, 23258–23266, <https://doi.org/10.1074/jbc.273.36.23258>
- 23 Smyth, E.M., Austin, S.C., Reilly, M.P. and FitzGerald, G.A. (2000) Internalization and sequestration of the human prostacyclin receptor. *J. Biol. Chem.* **275**, 32037–32045, <https://doi.org/10.1074/jbc.M003873200>
- 24 Vanhoutte, P.M. and Tang, E.H. (2008) Endothelium-dependent contractions: when a good guy turns bad!. *J. Physiol.* **586**, 5295–5304, <https://doi.org/10.1113/jphysiol.2008.161430>
- 25 Amraoui, F., Spijkers, L., Hassani Lahsinoui, H., Vogt, L., van der Post, J., Peters, S. et al. (2014) SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice. *PLoS ONE* **9**, e91897, <https://doi.org/10.1371/journal.pone.0091897>
- 26 Parkington, H.C., Coleman, H.A. and Tare, M. (2004) Prostacyclin and endothelium-dependent hyperpolarization. *Pharmacol. Res.* **49**, 509–514, <https://doi.org/10.1016/j.phrs.2003.11.012>
- 27 Gluais, P., Lonchamp, M., Morrow, J.D., Vanhoutte, P.M. and Feletou, M. (2005) Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. *Br. J. Pharmacol.* **146**, 834–845, <https://doi.org/10.1038/sj.bjp.0706390>
- 28 Gomez, E., Schwendemann, C., Roger, S., Simonet, S., Paysant, J., Courchay, C. et al. (2008) Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats. *Am. J. Physiol. Heart Circ. Physiol.* **295**, H2198–H2211, <https://doi.org/10.1152/ajpheart.00507.2008>
- 29 Xavier, F.E., Aras-Lopez, R., Arroyo-Villa, I., del Campo, L., Salas, M., Rossoni, L.V. et al. (2008) Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. *Br. J. Pharmacol.* **154**, 1225–1235, <https://doi.org/10.1038/bjp.2008.200>
- 30 Feletou, M., Verbeuren, T.J. and Vanhoutte, P.M. (2009) Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. *Br. J. Pharmacol.* **156**, 563–574, <https://doi.org/10.1111/j.1476-5381.2008.00060.x>
- 31 Baretella, O. and Vanhoutte, P.M. (2016) Endothelium-dependent contractions: prostacyclin and endothelin-1, partners in crime? *Adv. Pharmacol.* **77**, 177–208, <https://doi.org/10.1016/bs.apha.2016.04.006>
- 32 Weksler, B.B., Tack-Goldman, K., Subramanian, V.A. and Gay, Jr, W.A. (1985) Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. *Circulation* **71**, 332–340, <https://doi.org/10.1161/01.CIR.71.2.332>
- 33 Hla, T.T. and Bailey, J.M. (1989) Differential recovery of prostacyclin synthesis in cultured vascular endothelial vs. smooth muscle cells after inactivation of cyclooxygenase with aspirin. *Prostaglandins Leukot. Essent. Fatty Acids* **36**, 175–184, [https://doi.org/10.1016/0952-3278\(89\)90059-8](https://doi.org/10.1016/0952-3278(89)90059-8)
- 34 Katusic, Z.S. and Vanhoutte, P.M. (1989) Superoxide anion is an endothelium-derived contracting factor. *Am. J. Physiol.* **257**, H33–H37, <https://doi.org/10.1152/ajpheart.1989.257.1.H33>
- 35 Wilcox, C.S., Wang, C. and Wang, D. (2019) Endothelin-1-induced microvascular ROS and contractility in angiotensin-II-infused mice depend on COX and TP receptors. *Antioxidants (Basel)* **8**, 193, <https://doi.org/10.3390/antiox8060193>

- 36 Kappers, M.H., de Beer, V.J., Zhou, Z., Danser, A.H., Sleijfer, S., Duncker, D.J. et al. (2012) Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. *Hypertension* **59**, 151–157, <https://doi.org/10.1161/HYPERTENSIONAHA.111.182220>
- 37 Banfor, P.N., Franklin, P.A., Segreti, J.A., Widomski, D.L., Davidsen, S.K., Albert, D.H. et al. (2009) ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. *J. Cardiovasc. Pharmacol.* **53**, 173–178, <https://doi.org/10.1097/FJC.0b013e3181993493>
- 38 Sugimoto, T., Haneda, M., Sawano, H., Isshiki, K., Maeda, S., Koya, D. et al. (2001) Endothelin-1 induces cyclooxygenase-2 expression via nuclear factor of activated T-cell transcription factor in glomerular mesangial cells. *J. Am. Soc. Nephrol.* **12**, 1359–1368, <https://doi.org/10.1681/ASN.V1271359>
- 39 Kang, Y.J., Mbonye, U.R., DeLong, C.J., Wada, M. and Smith, W.L. (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. *Prog. Lipid Res.* **46**, 108–125, <https://doi.org/10.1016/j.plipres.2007.01.001>
- 40 Yang, T., Schnermann, J.B. and Briggs, J.P. (1999) Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. *Am. J. Physiol.* **277**, F1–F9, <https://doi.org/10.1152/ajprenal.1999.277.1.F1>
- 41 Schmedtje, Jr, J.F., Ji, Y.S., Liu, W.L., DuBois, R.N. and Runge, M.S. (1997) Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. *J. Biol. Chem.* **272**, 601–608, <https://doi.org/10.1074/jbc.272.1.601>
- 42 Ben-Batalla, I., Cubas-Cordova, M., Udonta, F., Wroblewski, M., Waizenegger, J.S., Janning, M. et al. (2015) Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. *Oncotarget* **6**, 6341–6358, <https://doi.org/10.18632/oncotarget.3437>
- 43 Lankhorst, S., Baelde, H.J., Verstijnen, J., Ten Tije, A.J., Thelen, M.H.M., Danser, A.H.J. et al. (2018) Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients. *J. Am. Soc. Hypertens.* **12**, e1–e7, <https://doi.org/10.1016/j.jash.2018.06.005>
- 44 Rabelink, T.J., de Boer, H.C. and van Zonneveld, A.J. (2010) Endothelial activation and circulating markers of endothelial activation in kidney disease. *Nat. Rev. Nephrol.* **6**, 404–414, <https://doi.org/10.1038/nrneph.2010.65>
- 45 Robinson, E.S., Khankin, E.V., Choueiri, T.K., Dhawan, M.S., Rogers, M.J., Karumanchi, S.A. et al. (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. *Hypertension* **56**, 1131–1136, <https://doi.org/10.1161/HYPERTENSIONAHA.110.160481>
- 46 Eskildsen, M.P., Hansen, P.B., Stubbe, J., Toff, A., Walter, S., Marcussen, N. et al. (2014) Prostaglandin I2 and prostaglandin E2 modulate human intrarenal artery contractility through prostaglandin E2-EP4, prostacyclin-IP, and thromboxane A2-TP receptors. *Hypertension* **64**, 551–556, <https://doi.org/10.1161/HYPERTENSIONAHA.113.03051>
- 47 Facemire, C.S., Nixon, A.B., Griffiths, R., Hurwitz, H. and Coffman, T.M. (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. *Hypertension* **54**, 652–658, <https://doi.org/10.1161/HYPERTENSIONAHA.109.129973>
- 48 Scappaticci, F.A., Skillings, J.R., Holden, S.N., Gerber, H.P., Miller, K., Kabbinar, F. et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J. Natl. Cancer Inst.* **99**, 1232–1239, <https://doi.org/10.1093/jnci/djm086>
- 49 Rothwell, P.M., Price, J.F., Fowkes, F.G., Zanchetti, A., Roncaglioni, M.C., Tognoni, G. et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet* **379**, 1602–1612, [https://doi.org/10.1016/S0140-6736\(11\)61720-0](https://doi.org/10.1016/S0140-6736(11)61720-0)
- 50 Flossmann, E., Rothwell, P.M. and British Doctors Aspirin Trial and the UK-TIA Aspirin Trial (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* **369**, 1603–1613, [https://doi.org/10.1016/S0140-6736\(07\)60747-8](https://doi.org/10.1016/S0140-6736(07)60747-8)
- 51 Matos, P. and Jordan, P. (2015) Beyond COX-inhibition: ‘side-effects’ of ibuprofen on neoplastic development and progression. *Curr. Pharm. Des.* **21**, 2978–2982, <https://doi.org/10.2174/1381612821666150514104608>
- 52 Baron, J.A., Sandler, R.S., Bresalier, R.S., Quan, H., Riddell, R., Lanasa, A. et al. (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. *Gastroenterology* **131**, 1674–1682, <https://doi.org/10.1053/j.gastro.2006.08.079>
- 53 Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K. et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. *N. Engl. J. Med.* **355**, 873–884, <https://doi.org/10.1056/NEJMoa061355>